Journal of Pharmacy And Bioallied Sciences

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 13  |  Issue : 5  |  Page : 624--628

Comparative evaluation of salivary visfatin levels in healthy and periodontally diseased patients before and after scaling and root planing


Greeshma Saseendran, Seba Abraham, Aparna M Nair, MK Reejamol 
 Department of Periodontics, PMS College of Dental Science and Research, Thiruvananthapuram, Kerala, India

Correspondence Address:
Greeshma Saseendran
Department of Periodontics, PMS College of Dental Science and Research, Thiruvananthapuram, Kerala
India

Abstract

Aim: The aim of this study was to compare the levels of salivary visfatin in healthy controls, patients with gingivitis and patients with chronic periodontitis and also to assess the outcome of scaling and root planing (SRP) on the levels of salivary visfatin in patients with gingivitis and chronic periodontitis. Materials and Methods: A total of 48 patients, both males and females, in the age group of 25–50 years were enrolled into three groups, based on their clinical parameters: Group I (Healthy controls - 16), Group II (Patients with gingivitis - 16), and Group III (Patients with chronic periodontitis - 16). Groups II and III were examined 2 months after SRP. The clinical parameters that were recorded include plaque index, modified gingival index, gingival bleeding index, pocket depth, and clinical attachment level. The samples of saliva were collected from each patient and the levels of visfatin were evaluated using enzyme-linked immunosorbent assay kit. Results: The mean concentration of salivary visfatin at baseline was found to be highest in Group III and lowest in Group I. A statistically significant reduction (P < 0.01) in the mean concentration of salivary visfatin and the clinical parameters were observed after 2 months of SRP. Conclusion: The levels of salivary visfatin can thus be considered as an inflammatory biomarker for periodontal diseases. However, future longitudinal prospective studies are needed to support these findings.



How to cite this article:
Saseendran G, Abraham S, Nair AM, Reejamol M K. Comparative evaluation of salivary visfatin levels in healthy and periodontally diseased patients before and after scaling and root planing.J Pharm Bioall Sci 2021;13:624-628


How to cite this URL:
Saseendran G, Abraham S, Nair AM, Reejamol M K. Comparative evaluation of salivary visfatin levels in healthy and periodontally diseased patients before and after scaling and root planing. J Pharm Bioall Sci [serial online] 2021 [cited 2021 Dec 3 ];13:624-628
Available from: https://www.jpbsonline.org/text.asp?2021/13/5/624/317520


Full Text



 Introduction



Periodontitis is defined as “an inflammatory disease of the supporting tissues of the teeth caused by specific microorganisms or groups of specific microorganisms, resulting in progressive destruction of the periodontal ligament and alveolar bone with increased probing depth formation, recession, or both.”[1] In response to these infection causing microorganisms, the host releases several pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), IL-6, and prostaglandin E2 (PGE2) which in turn promotes the action of matrix metalloproteinase (MMPs) in the periodontium, resulting in the degradation of connective tissue matrix and stimulation of alveolar bone resorption. These cytokines circulate to gingival crevicular fluid (GCF) and ultimately reach and accumulate in saliva,[2] and serve as possible salivary biomarkers of periodontal disease.[3]

Salivary biomarkers are now used for early detection, risk assessment, and monitoring of treatment response in periodontitis.[4],[5] Clinically, saliva is a very useful biological liquid that contains various biomarkers such as IL-1b, IL-6, PGE2, and MMP-8 which provides added information than the classic clinical and radiographic results.[6] Unlike GCF, saliva can be collected easily by a noninvasive method. Thus, saliva can be used as a diagnostic tool for the assessment of periodontal disease.

Adipose tissue is a very active and complex metabolic endocrine organ[7] which expresses several adipokines and adipocytokines. Visfatin (pre-B-cell colony-enhancing factor) is a newly identified adipokine that is secreted by the visceral adipocytes. It was introduced by Fukuhara et al.[8] in 2005. It is a pro-inflammatory adipocytokine that is also produced by neutrophils following inflammatory stimuli.[9] It upregulates the release of several cytokines by monocytes. The multiple inflammatory actions of visfatin make this cytokine a suitable biomarker and as a diagnostic tool in periodontitis.

The aim of the present study was to compare the levels of salivary visfatin in healthy individuals and participants with gingivitis and chronic periodontitis and also to assess the effects of scaling and root planing (SRP) on the levels of salivary visfatin in participants with gingivitis and chronic periodontitis.

 Materials and Methods



From February 2015 to July 2016, 48 patients aged 25–50 years were selected from the outpatient section of the Department of Periodontics, PMS College of Dental Science and Research, Trivandrum, Kerala, India. All the patients provided their consent to the protocol. The Institutional Ethical Committee of PMS College of Dental Science and Research (IEC No. PMS/IEC/2014/04(A)) provided the ethical clearance.

The included patients had ≤20 natural teeth and no other diseases. The patients with the following conditions were excluded from the study: (1) received periodontal treatment in the past 6 months, (2) smoking and alcoholism, (3) chronic inflammatory diseases such as rheumatoid arthritis and bowel disease, (4) systemic diseases such as hypertension, diabetes mellitus (5) aggressive periodontitis, (6) consumption of antibiotics and anti-inflammatory drugs since 6 months, and (7) pregnancy and lactation.

Based on Plaque Index (PI), Modified Gingival Index (MGI), Gingival Bleeding Index (GBI), Probing Pocket Depth (PD), and Clinical Attachment Level (CAL), the patients were categorized into the following three groups: Group I: 16 (clinically healthy subjects who had no bleeding on probing(BOP), absence of gingival inflammation (GI=0), PD ≤ 3mm, and absence of clinical attachment loss (CAL=0));Group II: 16 (patients with gingivitis - BOP ≥10%, GI > 1, CAL =0 and PD ≤ 3 mm); Group III: 16 (patients with chronic periodontitis - GI > 1, PD ≥ 5mm in 30 % of sites, CAL > 3mm (AAP Classification) and radiographic evidence of alveolar bone loss). Group II and III patients received SRP and were examined after 2 months.

Periodontal examination

The periodontal status of all the patients was evaluated before performing SRP and again after 2 months, which included PI, MGI, GBI, PD, CAL, and gingival recession. A standard periodontal probe (PCP-UNC 15, Hu-Friedy, Chicago, IL, USA) was used to measure all clinical parameters.

Collection of saliva

Saliva samples were collected according to the circadian rhythm. Participants were refrained from eating or rinsing 60 min before the collection of saliva sample. The whole saliva was collected into a sterilized vial by letting the saliva accumulate in the mouth and then spitting out into an Eppendorf tube. About 2 ml of unstimulated saliva was collected from each participant and samples were immediately placed on cryobox maintained at −20°C and taken to the Biogenix Research Centre, Trivandrum, Kerala, and stored at −80°C until further determinations were done. Samples were thawed and analyzed within 6 months of collection.

Visfatin analysis

Each sample of saliva was pipetted into a fresh microcap tube and subjected to centrifugation for 10 min at 4000 revolutions per minute (rpm) at 4°C. The supernatant was transferred to clean microcap tubes using sterilized micropipette [Figure 1] and an enzyme-linked immunosorbent assay (ELISA) was performed immediately. The concentrations of visfatin were determined using an ELISA kit (Human Visfatin ELISA Kit, Bioassay Technology Laboratory). In the test well, 40 μl saliva samples, 10 μl visfatin antibodies, and 50 μl Streptavidin – HRP were added, covered with membrane, and incubated at 37°C for 60 min. About 30 ml of washing solution was prepared and the wells were washed five times with it. Human Visfatin Chromogen A (50 μl) and Chromogen B (50 μl) were added and shook gently, incubated for 10 min at 37°C. The color changed to blue. Stop solution (50 μl) was added to each well and blue color changed to yellow [Figure 2]. The values of the optical density were measured within 10 min.{Figure 1}{Figure 2}

The absorbance of the substrate color reaction was read on ELISA reader 3 using 450 nm as the primary wavelength. The total visfatin was expressed in nanograms (ng), and its concentration in each sample was calculated by dividing the amount of visfatin by the volume of sample (ng/ml).

Statistical analysis

The intragroup and intergroup comparison of mean salivary visfatin levels and mean of outcome parameters were performed using paired and unpaired t-tests, respectively. For post hoc multiple comparisons between groups, Scheffe multiple comparisons along with ANOVA were performed. For all statistical evaluations, P < 0.01 was considered statistically significant.

 Results



The mean salivary visfatin level at baseline was found to be highest in Group III and lowest in Group I [Table 1]. The mean salivary visfatin level at baseline among three groups was 19.2, 30.7, and 56.8 pg/mL, respectively (P < 0.01). Comparison of salivary visfatin levels before and after SRP in Groups II and III, and intergroup comparisons after SRP are shown in [Table 2] and [Table 3]. After 2 months of performing SRP in Groups II and III, the mean visfatin concentrations reduced to 20.9 pg/mL in Group II and 24.8 pg/mL in Group III. The intergroup comparisons between Groups I and III, and Groups II and III after 2 months of SRP were statistically significant. There was no significant difference between Groups I and II.{Table 1}{Table 2}{Table 3}

All the clinical parameters (PI, MGI, GBI, PD, and CAL) demonstrated a statistically significant (P < 0.01) improvement in groups II and III by 2 months after SRP when compared to that at baseline [Table 4].{Table 4}

 Discussion



Visfatin is a biological mediator that acts as a growth factor, cytokine, as well as an enzyme and has several pro-inflammatory functions. The existing evidence has demonstrated increased levels of visfatin and its mRNA expression in several inflammatory diseases. It can upregulate the expression of other key inflammatory cytokines such as IL-6, IL-1 β, and TNF-α in human monocytes.

The present study is the first of its kind that compared the levels of salivary visfatin in healthy patients and patients with gingivitis and chronic periodontitis, before and after the procedure of SRP. The levels of salivary visfatin concentration were highest in patients with Group III, followed by patients with Group II and Group I. The significant difference could be due to variations in the severity of periodontal disease, flow of GCF, differences in the number of immune cells migrating into the crevice,[10] as well as the composition of microorganisms. The cells of the periodontal ligament can also secrete visfatin locally and is stimulated by key periodontal pathogens such as Fusobacterium nucleatum and Porphyromonas gingivalis.[11]

On intergroup comparison, a statistically significant difference in the mean salivary visfatin concentrations was obtained. The results were in accordance with the study by Tabari et al.[12] Raghavendra et al.[13] and Pradeep et al.[14] demonstrated the highest concentrations of visfatin in both GCF and serum in patients with chronic periodontitis. The increased levels of salivary visfatin in patients with chronic periodontitis confirm the active secretion of visfatin by immune cells associated with periodontal disease activity.

The present study found a statistically significant reduction (P < 0.001) in the levels of salivary visfatin in patients with gingivitis and chronic periodontitis after 2 months of performing SRP when compared to that at baseline. Furthermore, statistically significant reductions were observed in the clinical parameters (MGI, GBI, and PD) in Groups II and III. This is same as the results obtained by Tabari et al.[10]

In the present study, the concentrations of salivary visfatin increased with the severity of the disease and decreased after SRP. An increase in the levels of pro-inflammatory cytokines such as IL-6, IL-Iβ, and TNF-α can significantly enhance the expression of visfatin. Thus, salivary visfatin can be considered as a potential biomarker of periodontal diseases that can be used to monitor the response to periodontal treatment. However, very few studies have evaluated the impact of periodontal treatment on the levels of visfatin. This study did not consider the body mass index of the enrolled patients.

 Conclusion



Based on the results of the present study, enhanced visfatin levels may play a role in the pathogenesis of periodontal diseases. Thus, salivary visfatin can be considered as an inflammatory biomarker in periodontal diseases that can assess the response to nonsurgical periodontal treatment. However, the role of visfatin in periodontal diseases can further be ascertained by conducting longitudinal studies with larger sample sizes.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Carranza F, Newman M, Takei H, Klokkevold, P. Carranza's Clinical Periodontology. 11th ed. St. Louis, Mo: Elsevier Saunders. 2012.p. 705-7.
2Miller CS, King CP Jr, Langub MC, Kryscio RJ, Thomas MV. Salivary biomarkers of existing periodontal disease: A cross-sectional study. J Am Dent Assoc 2006;137:322-9.
3Buduneli N, Kinane DF. Host-derived diagnostic markers related to soft tissue destruction and bone degradation in periodontitis. J Clin Periodontol 2011;38 Suppl 11:85-105.
4Khiste SV, Ranganath V, Nichani AS, Rajani V. Critical analysis of biomarkers in the current periodontal practice. J Indian Soc Periodontol 2011;15:104-10.
5Kinane DF, Preshaw PM, Loos BG, Working Group 2 of Seventh European Workshop on Periodontology. Host-response: Understanding the cellular and molecular mechanisms of host-microbial interactions Consensus of the Seventh European Workshop on Periodontology. J Clin Periodontol 2011;38 Suppl 11:44-8.
6Wright TA. Salivary diagnostic testing: A “game changer” for patient evaluation. Compend Contin Educ Dent 2011;32 Spec No 4:28-9.
7Flier JS, Flier EM. Biology of obesity. In: Wiener C, Fauci AS, Braunwald E, Kasper D, Hauser Sl, Longo Dl, et al., editors. Harrison's Principles of Internal Medicine. New York: The Mcgraw-Hill Companies Inc.; 2007. p. 462-72.
8Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30.
9Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58.
10Tabari ZA, Ghaedi FB, Azadmehr A, Nohekhan A, Tabrizi MA, Ardakani MR, et al. Salivary visfatin concentration in response to non-surgical periodontal therapy. J Clin Diagn Res 2015;9:ZC05-8.
11Sapna G, Gokul S, Bagri-Manjrekar K. Matrix metalloproteinases and periodontal diseases. Oral Dis 2014;20:538-50.
12Tabari ZA, Azadmehr A, Nohekhan A, Naddafpour N, Ghaedi FB. Salivary visfatin concentrations in patients with chronic periodontitis. J Periodontol 2014;85:1081-1085.
13Raghavendra NM, Pradeep AR, Kathariya R, Sharmaa A, Rao NS. Effect of non surgical periodontal therapy on gingival crevicular fluid and serum visfatin concentration in periodontal health and disease. Dis Markers 2012;32:383-8.
14Pradeep AR, Raghavendra NM, Prasad MV, Kathariya R, Patel SP, SharmaA. Gingival crevicular fluid and serum visfatin concentration: Their relationship in periodontal health and disease. J Periodontol 2011;82:1314-9.